Switch costimulatory receptors

Patent metadata

Field	Value
Publication number	US-10981969-B2
Application number	US-201214232557-A
Country	US
Kind code	B2
Filing date	Jul 27, 2012
Priority date	Jul 29, 2011
Publication date	Apr 20, 2021
Grant date	Apr 20, 2021

Abstract

The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide that is associated with a negative signal and the second domain is a polypeptide that is associated with a positive signal. Thus, the invention encompasses switch receptors that are able to switch negative signals to positive signals for enhancement of an immune response.

First claim

What is claimed is:

1. A fusion protein comprising an extracellular domain, a transmembrane domain, and an intracellular domain, wherein said extracellular domain is an extracellular domain of a signaling protein that is associated with a negative signal, said intracellular domain comprises an intracellular domain of a signaling protein that is associated with a positive signal and an intracellular domain of the CD3-zeta chain, and said transmembrane domain is a transmembrane domain of a signaling protein that is associated with a negative signal or a transmembrane domain of a signaling protein that is associated with a positive signal,
(i) wherein said signaling protein that is associated with a negative signal, said transmembrane domain, and said signaling protein that is associated with a positive signal are respectively selected from the group consisting of
B- and T-lymphocyte attenuator (BTLA), CD28 transmembrane domain, and CD28;
BTLA, BTLA transmembrane domain, and inducible T-cell co-stimulator (ICOS);
BTLA, ICOS transmembrane domain, and ICOS;
BTLA, ICOS transmembrane domain, and CD27; and
BTLA, BTLA transmembrane domain, and CD27, wherein when said fusion protein is displayed on a cell and when said extracellular domain of BTLA receives a negative signal from binding with HVEM, said fusion protein is able to switch said negative signal to a positive signal in said cell for enhancement of an immune response, or
(ii) wherein said signaling protein that is associated with a negative signal, said transmembrane domain, and said signaling protein that is associated with a positive signal, respectively, are programmed cell death-1 (PD-1), ICOS transmembrane domain, and ICOS, wherein when said fusion protein is displayed on a cell and when said extracellular domain of PD-1 receives a negative signal from binding with PD-L1, said fusion protein is able to switch said negative signal to a positive signal in said cell for enhancement of an immune response.

2. The fusion protein of claim 1 , wherein said signaling protein that is associated with a negative signal is BTLA.

3. The fusion protein of claim 1 , wherein said signaling protein that is associated with a negative signal, said transmembrane domain, and said signaling protein that is associated with a positive signal are respectively selected from the group consisting of:
BTLA, BTLA transmembrane domain, and inducible T-cell co-stimulator (ICOS); and
BTLA, ICOS transmembrane domain, and ICOS.

4. A cell engineered to express said fusion protein of claim 1 .

5. The cell of claim 4 further comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain of a specific antibody and an intracellular domain of the CD3-zeta chain.

6. A vector comprising a nucleic acid encoding the fusion protein of claim 1 .

7. A method of treating a cancer patient, said method comprising administering to said patient a T cell genetically engineered to express said fusion protein of claim 1 .

8. The method of claim 7 , wherein said T cell is further genetically engineered to express a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain of a specific antibody and an intracellular domain of the CD3-zeta chain.

9. The method of claim 8 , wherein said T cell is an autologous T cell.

10. A fusion protein comprising an extracellular domain and an intracellular domain, wherein said extracellular domain is an extracellular domain of a signaling protein that is associated with a negative signal and said intracellular domain comprises an intracellular domain of a signaling protein that is associated with a positive signal and an intracellular domain of the CD3-zeta chain,
(i) wherein said signaling protein that is associated with a negative signal and said signaling protein that is associated with a positive signal are respectively selected from the group consisting of B- and T-lymphocyte attenuator (BTLA) and CD28; BTLA and inducible T-cell co-stimulator (ICOS); and BTLA and CD27, wherein when said fusion protein is displayed on a cell and when said extracellular domain of BTLA receives a negative signal from binding with HVEM, said fusion protein is able to switch said negative signal to an intracellular positive signal in said cell for enhancement of an immune response, or
(ii) wherein said signaling protein that is associated with a negative signal and said signaling protein that is associated with a positive signal are respectively selected from the group consisting of programmed cell death-1 (PD-1) and ICOS; and PD-1 and CD27, wherein when said fusion protein is displayed on a cell and when said extracellular domain of PD-1 receives a negative signal from binding with PD-L1, said fusion protein is able to switch said negative signal to a positive signal in said cell for enhancement of an immune response.

11. The fusion protein of claim 10 , wherein the fusion protein comprises a transmembrane domain selected from an ICOS transmembrane domain, a BTLA transmembrane domain, and a CD28 transmembrane domain.

12. The fusion protein of claim 10 , wherein said signaling protein that is associated with a negative signal and said signaling protein that is associated with a positive signal are respectively BTLA and ICOS.

13. A cell engineered to express the fusion protein of claim 10 .

14. The cell of claim 13 , further comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain of a specific antibody and an intracellular domain of the CD3-zeta chain.

15. A vector comprising a nucleic acid encoding the fusion protein of claim 10 .

16. A fusion protein comprising an extracellular domain, a transmembrane domain, and an intracellular domain, wherein said extracellular domain is an extracellular domain of a signaling protein that is associated with a negative signal, said intracellular domain comprises an intracellular domain of a signaling protein that is associated with a positive signal, and said transmembrane domain is a transmembrane domain of a signaling protein that is associated with a negative signal or a transmembrane domain of a signaling protein that is associated with a positive signal, wherein said fusion protein is encoded by the nucleic acid sequence of SEQ ID NO: 6, 7, 8, 9, 10, or 11.

17. A cell engineered to express a fusion protein, said fusion protein comprising an extracellular domain and an intracellular domain, wherein said extracellular domain is an extracellular domain of a signaling protein that is associated with a negative signal and said intracellular domain is an intracellular domain of a signaling protein that is associated with a positive signal,
(i) wherein said signaling protein that is associated with a negative signal and said signaling protein that is associated with a positive signal are respectively selected from the group consisting of B- and T-lymphocyte attenuator (BTLA) and CD28; BTLA and inducible T-cell co-stimulator (ICOS); and BTLA and CD27, wherein when said fusion protein is displayed on a cell and when said extracellular domain of BTLA receives a negative signal from binding with HVEM, said fusion protein is able to switch said negative signal to an intracellular positive signal in said cell for enhancement of an immune response, or
(ii) wherein said signaling protein that is associated with a negative signal and said signaling protein that is associated with a positive signal are respectively selected from the group consisting of programmed cell death-1 (PD-1) and ICOS; PD-1 and CD28; and PD-1 and CD2

Assignees

• June Carl H
• Zhao Yangbing
• Univ Pennsylvania

Inventors

• June Carl H
• Zhao Yangbing

Classifications

• C07K14/7051 Primary

  T-cell receptor (TcR)-CD3 complex · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/421

  Immunoglobulin superfamily · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title